Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares conducted on March 11, 2026, and filed on March 12, 2026. The transaction was executed by BNP Paribas SA as part of GSK's existing share buyback programme, pursuant to a non-discretionary agreement announced on February 17, 2026. The purchased shares are held as Treasury shares.
Key Financial Metrics
The filing details specific share repurchase activity rather than operational financial results (revenue, profit, or cash flow are not provided in this document).
- Shares Purchased (March 11, 2026): 513,409 ordinary shares.
- Price Range: Lowest price paid was 2,047.00 GBp; Highest price paid was 2,078.00 GBp.
- Volume-Weighted Average Price (VWAP): 2,061.69 GBp.
- Cumulative Purchases (since Feb 17, 2026): 8,690,409 ordinary shares.
- Total Treasury Shares Held: 248,581,503 ordinary shares.
- Ordinary Shares in Issue (excluding Treasury): 4,067,587,319.
- Treasury Voting Rights: 6.11% of total voting rights.
Trading Venue Breakdown (March 11, 2026)
| Venue | Shares Purchased | Highest Price (GBp) | Lowest Price (GBp) | VWAP (GBp) |
|---|---|---|---|---|
| BATE | 74,409 | 2,077.00 | 2,047.00 | 2,061.60 |
| CHIX | 139,866 | 2,078.00 | 2,047.00 | 2,061.99 |
| XLON | 299,134 | 2,077.00 | 2,047.00 | 2,061.58 |
Material Changes
Since the announcement of the non-discretionary agreement on February 17, 2026, GSK has purchased an aggregate of 8,690,409 ordinary shares. The specific transaction on March 11, 2026, increased the total number of shares held in treasury to 248,581,503. Consequently, the percentage of voting rights attributable to treasury shares stands at 6.11%.
Guidance, Outlook, and Risks
The filing contains no operational guidance, revenue outlook, or management commentary regarding business performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks and uncertainties. Investors are referred to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2025 for a detailed description of these risks.
Key Facts for Investor Verification
- Verify the total number of shares in issue (4,067,587,319) to calculate accurate ownership percentages under FCA Disclosure Guidance and Transparency Rules.
- Confirm the 6.11% voting rights held in treasury, which do not carry voting rights.
- Note that the buyback is being executed via a non-discretionary agreement with BNP Paribas SA.
- Review the Form 20-F for 2025 for comprehensive risk factors associated with the company's operations and the buyback programme.